Aβ寡聚体与阿尔茨海默病研究进展  

Advances in the study of Aβ oligomers and Alzheimer's disease

作　　者：王国庆(综述) 曹云鹏(审校)[1] WANG Guoqing;CAO Yunpeng(Department of Neurology,The First Hospital of China Medical University,Shenyang 110001,China)

机构地区：[1]中国医科大学附属第一医院神经内科,辽宁沈阳110000 [2]辽阳市中心医院神经内科,辽宁辽阳111000

出　　处：《中风与神经疾病杂志》2023年第7期579-583,共5页Journal of Apoplexy and Nervous Diseases

基　　金：国家自然科学基金(81870819)。

摘　　要：阿尔茨海默病(Alzheimer's disease,AD)是一种以记忆损害为主要表现渐进性发展的神经退行性疾病,随着老龄化社会发展发病率呈上升趋势,带来巨大的社会经济负担。近年来的研究使AD经典发病机制淀粉样蛋白级联假说受到了挑战,Aβ寡聚体(Aβoligomers,AβOs)的毒性作用得到了一致性的认可,可能是AD发病的触发因素。关于Aβ寡聚体具体来源、结构和致病机制的认识还不充分,可能不同类型寡聚体致病毒性不一致,作用机制有差别。本文综述了对Aβ寡聚体的新近认知,以及它们的结构特点和致病作用,以求更好的理解Aβ寡聚体和AD的关系,为之后的研究提供可能的方向。Alzheimer's disease(AD)is a progressive neurodegenerative disease with memory impairment as the main manifestation.With the development of an aging society,the incidence of AD is on the rise,bringing a huge social and economic burden.In recent years,the classical amyloid cascade hypothesis in the pathogenesis of AD has been challenged,and the toxic effects of Aβoligomers(AβOs)have been consistently recognized,which may be a trigger for the pathogenesis of AD.The specific source,structure,and pathogenic mechanism of Aβoligomers are not fully understood.It is possible that different types of oligomers are not consistent in pathogenicity and toxicity,and their mechanisms of action are different.This article reviews the recent understanding of Aβoligomers,as well as their structural characteristics and pathogenic effects,to better understand the relationship between Aβoligomers and AD,and provide possible directions for future research.

关 键 词：阿尔茨海默病 淀粉样蛋白 AΒ寡聚体 神经毒性 单克隆抗体 

分 类 号：R749.16[医药卫生—神经病学与精神病学]